ACADIA Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1993-07-16
- Employees
- 598
- Market Cap
- $2.6B
- Website
- http://www.acadia.com
Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
- Conditions
- Dementia-related Psychosis
- Interventions
- First Posted Date
- 2017-10-30
- Last Posted Date
- 2021-06-21
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 392
- Registration Number
- NCT03325556
- Locations
- 🇺🇦
Municipal Institution "Odesa Regional Medical Center of Mental Health", Department #18, Odesa, Ukraine
🇺🇸University of Tennessee Medical Center, Knoxville, Tennessee, United States
🇷🇸Institut of Mental Health, Belgrade, Serbia
The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study
- Conditions
- Parkinson Disease Psychosis
- Interventions
- Other: Real-world, non-interventional
- First Posted Date
- 2017-05-15
- Last Posted Date
- 2021-08-06
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 764
- Registration Number
- NCT03152292
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸MS Center of Atlanta, Atlanta, Georgia, United States
🇺🇸Alpha Neurology PC, Staten Island, New York, United States
Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia
- First Posted Date
- 2017-04-20
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 996
- Registration Number
- NCT03121586
- Locations
- 🇺🇸
141-Hassman Research Institute, Berlin, New Jersey, United States
🇺🇸114-Northwestern University, Chicago, Illinois, United States
🇺🇦582-SI Institute of Neurology,Psychiatry&Narcology of NAMSU, Kharkiv, Ukraine
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
- Conditions
- Agitation and Aggression in Alzheimer's Disease
- Interventions
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2020-04-09
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 79
- Registration Number
- NCT03118947
- Locations
- 🇺🇸
Miami Jewish Health Systems, Miami, Florida, United States
🇺🇸Acadia Hospital, Bangor, Maine, United States
🇨🇱Especialidades Medicas L y S, Santiago, Chile
Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)
- Conditions
- Adjunctive Treatment of Major Depressive Disorder
- Interventions
- Other: Placebo
- First Posted Date
- 2017-01-12
- Last Posted Date
- 2019-11-14
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 207
- Registration Number
- NCT03018340
- Locations
- 🇺🇸
Carolina Clinical Trials, Inc., Charleston, South Carolina, United States
🇺🇸Woodland Research Northwest, Rogers, Arkansas, United States
🇺🇸Altea Research, Las Vegas, Nevada, United States
Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)
- Conditions
- Agitation and Aggression in Alzheimer's Disease
- Interventions
- First Posted Date
- 2016-12-14
- Last Posted Date
- 2019-03-28
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 111
- Registration Number
- NCT02992132
Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)
- First Posted Date
- 2016-11-22
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 396
- Registration Number
- NCT02970292
Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)
- First Posted Date
- 2016-11-22
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 403
- Registration Number
- NCT02970305
Expanded Access of Pimavanserin for Patients With PD Psychosis
- Conditions
- Parkinson's Disease Psychosis
- First Posted Date
- 2016-05-05
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Registration Number
- NCT02762591
A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis
- Conditions
- Alzheimer's Disease Psychosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-01-14
- Last Posted Date
- 2017-10-25
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 181
- Registration Number
- NCT02035553